On August 1st New Jersey's full legislature gave approval to Assembly Bill 457 which would add post traumatic stress disorder (PTSD) as a qualifying medical cannabis condition. The vote in the Senate was 29 to 9; the vote in the Assembly was 56 to 13.

Now, the measure sits on the desk of Governor Chris Christie, who has the option of signing it into law, allowing it to become law without his signature, or vetoing it. We are calling Governor Christie to quickly sign it into law, allowing those suffering from the ailment to use a medicine that research has continually shown is beneficial.

For example, a government-funded study released in 2014 using human trials found that “the cannabinoid system may serve as a promising target for innovative intervention strategies (e.g. pharmacological enhancement of exposure-based therapy) in PTSD and other fear learning-related disorders.”

A separate study released last year found that; “When inhaled or delivered orally or transdermally, cannabinoids (the psychoactive components of unrefined marijuana and various derivative products) activate endogenous cannabinoid receptors, modulating neurotransmitter release and producing a wide range of central nervous system effects, including increased pleasure and alteration of memory processes.... Those effects provide a pharmacologic rationale for the use of cannabinoids to manage the three core PTSD symptom clusters: reexperiencing, avoidance and numbing, and hyperarousal.”

If signed into law, New Jersey would join Michigan, California, Illinois, Connecticut, Delaware, Maine, Massachusetts, New Mexico, Arizona, Washington, Rhode Island and Oregon as states that recognize PTSD as a qualifying medical cannabis condition.

According to the National Institute of Health, PTSD affects about 7.7 million people.